Objective: Generic drugs typically are less expensive than branded products; however, several factors can limit generic drug utilization. This study assesses the associations of patient factors with generic olanzapine initiation and substitution.
Methods: A retrospective new user cohort study was conducted using the 2011-2012 Medicaid administrative claims data. Beneficiaries continuously enrolled during the 6 month washout period prior to their initial oral brand or generic olanzapine prescription were included and followed up to 12 months. Among brand olanzapine new users, time to generic substitution and competing risk outcomes was estimated using the Fine-Gray cumulative incidence function. Patient demographic and health service utilization factors were assessed in the multivariate cause-specific hazards model.
Results: Among olanzapine new users, 70.7% patients initiated generic treatment. Beneficiaries aged ≥21, and living in the Midwest and West regions were more likely to initiate generic olanzapine. Among brand new users, 28.2% switched to generic olanzapine, 23.6% switched to an alternative atypical antipsychotic treatment and 38.0% discontinued within 12 months. Beneficiaries who resided in urban areas (adjusted hazard ratio [AHR) = 0.53, 95% CI = 0.37-0.75) and had prior hospitalizations (AHR = 0.85, 95% CI = 0.75-0.96) had lower rates of generic substitution, whereas those with emergency department (ED) visits (AHR = 1.06, 95% CI = 1.02-1.10) had a higher rate of generic substitution. In addition, beneficiaries in different age subgroups also had different rates of generic substitution in different regions.
Conclusion: Medicaid beneficiaries' age, geographic region, prior hospitalization and ED utilization were associated with generic olanzapine initiation and substitution. Tailored educational outreach targeting these patient subgroups might improve generic olanzapine utilization.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/03007995.2021.1882413 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Olanzapine-Induced Thrombocytopenia in a Patient With Chronic Schizophrenia: A Case Report.
Cureus
November 2024
Psychiatry, Al Amal Psychiatric Hospital, Emirates Health Services, Dubai, ARE.
Olanzapine, a second-generation antipsychotic widely used for schizophrenia, is primarily known for its efficacy in managing both positive and negative symptoms. While its metabolic side effects are well-documented, hematologic complications such as thrombocytopenia are rare and often underrecognized. A 30-year-old Middle Eastern male with a longstanding history of schizophrenia developed persistent thrombocytopenia after several years of olanzapine use, with platelet counts consistently below the normal range.
View Article and Find Full Text PDFEarly adolescent second-generation antipsychotic exposure produces long-term, post-treatment increases in body weight and metabolism-associated gene expression.
Pharmacol Biochem Behav
December 2024
Pennington Biomedical Research Center, Baton Rouge, LA 70808, United States of America.
The use of second-generation antipsychotic (SGA) medications in pediatric patients raises concerns about potential long-term adverse outcomes. The current study evaluated the long-term effects of treatment with risperidone or olanzapine on body weight, caloric intake, serum insulin, blood glucose, and metabolism-associated gene expression in C57Bl/6J female mice. Compared to mice treated with vehicle, female mice treated with risperidone or olanzapine gained weight at higher rates during treatment and maintained higher body weights for months following treatment cessation.
View Article and Find Full Text PDFPrescribing of antipsychotics for people diagnosed with severe mental illness in UK primary care 2000-2019: 20-year investigation of who receives treatment, with which agents and at what doses.
Br J Psychiatry
December 2024
Division of Psychiatry, University College London, London, UK.
Background: Contemporary data relating to antipsychotic prescribing in UK primary care for patients diagnosed with severe mental illness (SMI) are lacking.
Aims: To describe contemporary patterns of antipsychotic prescribing in UK primary care for patients diagnosed with SMI.
Method: Cohort study of patients with an SMI diagnosis (i.
Consumption of Sugar-Sweetened Beverages in People with Severe Mental Illness: A Community-Based Cohort Study.
J Multidiscip Healthc
December 2024
Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Objective: Excess mortality in mentally ill is largely due to high rates of physical illnesses that lead to worse health outcomes. This study examines the intake of added sugar from sugar-sweetened beverages (SSBs) and factors associated with poor mental and physical health in people with severe mental illness.
Methods: Data were collected as part of the standard care of consumers attending the Collaborative Centre for Cardiometabolic Health in Psychosis clinics where a diet history is taken by a dietitian.
The Preventive Effect of Zinc Sulfate against Olanzapine-Induced Testicular Toxicity in Male Rats.
Biol Trace Elem Res
December 2024
Institute of Specific Prophylaxis and Tropical Medicine [ISPTM], Center for Pathophysiology, Infectiology and Immunology [CePII], Ocular Immunology & Infectiology, Medical University of Vienna, Vienna, Austria.
Male infertility is a complex and multifactorial clinical condition affecting a large population attributed to several factors, including perturbation in oxidative stress and the level of essential trace elements. Oxidative stress exerts multiple issues related to reproductive health, including male infertility, decreased sperm motility, sperm DNA damage, and an increased susceptibility to genetic disorders. Besides chemical toxins and food allergens in junk food items, many drugs can also lead to male infertility.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!